Neurimmune Holding

Switzerland
Schlieren, Zurich, Switzerland, CH-8952

Company profile

Neurimmune Holding company profile

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet medical needs. With its unique Reverse Translational Medicine™ platform, Neurimmune creates recombinant human-derived monoclonal antibodies with biophysical characteristics closely resembling those occurring in healthy elderly. These antibodies display unique properties such as target selectivity, superior pharmacodynamics and low immunogenicity, resulting in superior risk profiles and excellent efficacy. Neurimmune’s pipeline comprises programs for a broad variety of disease related targets and specific target conformations. These include misfolded, oligomeric, fibrillar or post-translationally modified forms of disease-associated proteins as well as physiological conformations involved in major disease pathways.

Business identity

Contact email
[email protected]
Phone number
41 44 755 46 46
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2006-01-01, Year

Headquarters

Postal code
CH-8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
1
Total equity funding
$150M
Last funding
Series Unknown / $150M / 2017-10-25
Last equity funding
Series Unknown / $150M
Investors
1
Lead investors
1
Founders
2
Articles
25

Founders and investors

Founders

Jan GrimmRoger M Nitsch

Lead investors

Biogen

Investors

Biogen